iShares iBonds Dec 2023 Term Treasury (IBTD) ETF Holdings & Analysis
ETFOther
What IBTD does
This fund commits a minimum of 90% of its assets to U.S. Treasury securities, which BlackRock Fund Advisors (BFA) chooses to closely align with the underlying index's performance. More generally, at least 80% of its portfolio will be invested in the specific securities that constitute that benchmark index. This index is exclusively comprised of publicly-issued U.S. government debt instruments, all of which are set to mature within a window stretching from January 1, 2023, to December 15, 2023. The fund operates with a non-diversified investment strategy.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| BLK CSH FND TREASURY SL AGENCY | 99.47% | |
| USD CASH | 0.53% |
Sector allocation
| Cash & Others | 100.00% |
Geographic allocation
| Other | 100.00% |
PortView Portfolio Insights
PortView analyzes how IBTD fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze IBTD in PortView →Related securities
Related stocks
Frequently asked questions
- What does IBTD track?
- IBTD is the iShares iBonds Dec 2023 Term Treasury ETF, a Other ETF.
- What is the expense ratio of IBTD?
- Expense ratio data for IBTD is shown on the page when available from our data provider.
- What are the largest holdings in IBTD?
- Top holdings include BLK CSH FND TREASURY SL AGENCY, USD CASH.
- How can PortView analyze IBTD overlap with other ETFs?
- PortView computes the holdings overlap between IBTD and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.